Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry

被引:28
作者
Frerichs, VA [1 ]
Zaranek, C [1 ]
Haas, CE [1 ]
机构
[1] SUNY Buffalo, Dept Pharm Practice, Pharmacotherapy Res Ctr, Core Analyt Lab, Buffalo, NY 14260 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 824卷 / 1-2期
关键词
omeprazole; midazolam; analysis; LCMS; CYP2C19;
D O I
10.1016/j.jchromb.2005.07.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A method has been developed and validated for the quantitation of midazolam, alphahydroxy-midazolam, omeprazole, and hydroxyomeprazole from one 250 mu L sample of human plasma using high performance liquid chromatography coupled to tandem mass spectrometry. The method was validated for a daily working range of 0.400-100 ng/mL, with limits of detection between 2 and 15 pg/mL. The inter-assay variation was less than 15% for all analytes at four control concentrations and the samples were stable for three freeze-thaw cycles under the analysis conditions and 24 h in the post-preparative analysis matrix. This method was used to analyze samples in support of clinical studies probing the activity of the cytochrome P-450 enzyme system. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 26 条
[1]  
*AM CHEM SOC, 2004, SCIF SCHOL ONL 2004
[2]   PHOTOCHEMICAL DECOMPOSITION OF MIDAZOLAM .4. STUDY OF PH-DEPENDENT STABILITY BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
ANDERSIN, R ;
TAMMILEHTO, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 123 (02) :229-235
[3]   DOSE OF MIDAZOLAM SHOULD BE REDUCED DURING DILTIAZEM AND VERAPAMIL TREATMENTS [J].
BACKMAN, JT ;
OLKKOLA, KT ;
ARANKO, K ;
HIMBERG, JJ ;
NEUVONEN, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (03) :221-225
[4]   THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY [J].
BALIAN, JD ;
SUKHOVA, N ;
HARRIS, JW ;
HEWETT, J ;
PICKLE, L ;
GOLDSTEIN, JA ;
WOOSLEY, RL ;
FLOCKHART, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :662-669
[5]  
BLACK RS, DETERMINATION OMEPRA
[6]   CHEMICAL-REACTIONS OF OMEPRAZOLE AND OMEPRAZOLE ANALOGS .2. KINETICS OF THE REACTION OF OMEPRAZOLE IN THE PRESENCE OF 2-MERCAPTOETHANOL [J].
BRANDSTROM, A ;
BERGMAN, NA ;
LINDBERG, P ;
GRUNDEVIK, I ;
JOHANSSON, S ;
TEKENBERGSHJELTE, L ;
OHLSON, K .
ACTA CHEMICA SCANDINAVICA, 1989, 43 (06) :549-568
[7]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[8]  
Food and Drug Administration (FDA). Guidance for Industry, 1999, GUID IND IN VIV DRUG
[9]   Validation of the five-drug ''Pittsburgh cocktail'' approach for assessment of selective regulation of drug-metabolizing enzymes [J].
Frye, RF ;
Matzke, GR ;
Adedoyin, A ;
Porter, JA ;
Branch, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) :365-376
[10]   Sample preparation for LC/MS/MS: Analyzing biological and environmental samples [J].
Henion, J ;
Brewer, E ;
Rule, G .
ANALYTICAL CHEMISTRY, 1998, 70 (19) :650A-656A